The Upstream and Downstream products of Carbamimidothioic acid, [2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl ester, dihydrochloride

Carbamimidothioic acid, [2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl ester, dihydrochloride, also known as CB-5055, is an investigational drug that is currently in clinical trials for the treatment of various neurological disorders.
It is a synthetic compound that is designed to act on specific receptors in the brain and to have a positive effect on cognitive function.

One of the unique features of CB-5055 is that it is an upstream product, meaning that it is a precursor to other downstream products that have specific therapeutic benefits.
In the chemical industry, upstream products are the raw materials that are used to create downstream products.
In the case of CB-5055, it is the starting point for a series of chemical reactions that lead to the creation of the final product, which is the active ingredient in the drug.

CB-5055 is a derivative of carbamimidothioic acid, which is a naturally occurring substance that is found in small amounts in certain foods.
The molecule is also related to other compounds that have been used in medicine, such as thiotepa, which is a chemotherapy drug that has been used to treat cancer.

Once CB-5055 has been synthesized in the laboratory, it undergoes a series of chemical reactions that lead to the formation of the final compound.
This process is known as chemical synthesis, and it involves the use of various chemical reagents and conditions to create the desired product.

One of the key steps in the synthesis of CB-5055 is the addition of the methyl ester group to the molecule.
This is done by treating the CB-5055 precursor with a compound called methyl iodide under conditions that are highly specific.
This reaction is a typical example of an esterification reaction, which is a common chemical reaction in which an organic acid is converted to an ester by reaction with an alcohol.

Once the methyl ester group has been added to CB-5055, it is then converted to the dihydrochloride salt, which is the final form of the compound.
This is done by treating the methyl ester with hydrochloric acid, which results in the formation of the salt.
The dihydrochloride salt is then isolated from the reaction mixture and dried to remove any residual solvents.

The final product, CB-5055 dihydrochloride, is a white to off-white powder that is soluble in water.
It has a molecular weight of 441.
9 g/mol and a calculated pKa of 5.
53.
It is a potent and selective antagonist of the N-methyl-D-aspartate (NMDA) receptor, which is a type of glutamate receptor that is involved in the regulation of synaptic plasticity and learning.

CB-5055 dihydrochloride is currently in clinical trials for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
It has been shown to have a positive effect on cognitive function in animal models of these diseases, and it is hoped that it may have similar effects in humans.

In conclusion, CB-5055 dihydrochloride is an upstream product that is synthesized through a series of chemical reactions from its precursor, carbamimidothioic acid.
The final product is a white to off-white powder that is used in clinical trials for the treatment of neurological disorders.
Its chemical synthesis involves a series of specific reactions that are carried out under controlled conditions in the laboratory.